Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab + metronidazole
- Development stage
- Phase 3
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
A combination therapy consisting of adalimumab (a TNF-alpha inhibitor) and metronidazole (a nitroimidazole antibiotic). This combination has been studied specifically for preventing post-operative recurrence in high-risk Crohn's disease patients following intestinal resection. Adalimumab binds to TNF-alpha and blocks its interaction with surface TNF receptors, while metronidazole provides antimicrobial effects. Studies have shown this combination to be superior to thiopurines with metronidazole in preventing early disease recurrence.
02
Targets
Beyond the preview
Go deeper on adalimumab + metronidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab + metronidazole.